Value Creation
Autism Spectrum Disorders, as reported by the Centers for Disease Control and Prevention, affects approximately 1 out of 150 children. Early identification and therapeutic intervention have been shown to improve long term prognosis. A London School Economics Study concluded that Britain’s lifelong cost of care can be reduced by two-thirds with early diagnosis and intervention, a savings of $60 billion. IntegraGen is committed to identifying genes and developing molecular diagnostic tests that will assist clinicians in their pursuit of early identification of affected individuals.
Project Status
IntegraGen has developed a four gene panel that will enable clinicians to identify individuals at high-risk to develop autism. Clinical trials to validation these tests are ongoing.
Strategic Alliances
IntegraGen seeks funding and alliances with private, clinical and academic institutions to bring additional Autism products through the development pipeline. IntegraGen has, and will continue to, in-license intellectual property from world-class researchers to improve the utility and breadth of our offerings.
sources: www.medicalnewstoday.com www.cdc.gov/ncbddd/autism/overview.htm
